Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

2.17
+0.14006.90%
Post-market: 2.17-0.0005-0.02%19:41 EDT
Volume:6.16M
Turnover:13.34M
Market Cap:748.65M
PE:-3.33
High:2.21
Open:2.05
Low:2.05
Close:2.03
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:267.00M
Volume Ratio:1.24
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.72
PE(LYR):-2.51

Loading ...

Allogene stockholders approve increase in authorized common shares to 800 million

Reuters
·
Jun 23

Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Dow Jones
·
Jun 11

Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026

Reuters
·
May 29

Allogene Therapeutics - Appoints Zachary Roberts as President and CEO Effective July 1, 2026

THOMSON REUTERS
·
May 29

Allogene Therapeutics Announces Planned CEO Succession

THOMSON REUTERS
·
May 29

Allogene Therapeutics - David Chang to Transition From President and CEO, Will Remain on Board

THOMSON REUTERS
·
May 29

Allogene Therapeutics to present at TD Cowen Oncology Innovation Summit

Reuters
·
May 26

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 14

Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Allogene Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Allogene Therapeutics ends China cell therapy deal with Overland

Reuters
·
May 14

Allogene Therapeutics Q1 Net Loss Narrows

MT Newswires Live
·
May 14

BRIEF-Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing

Reuters
·
May 14

Allogene Therapeutics Inc - No Termination Payments Made in Connection With Termination Agreement - SEC Filing

THOMSON REUTERS
·
May 14

Allogene Therapeutics Inc - Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026 - SEC Filing

THOMSON REUTERS
·
May 14

Allogene Therapeutics Inc - to Hold About 3% of Overland Equity After Surrendering Portion for No Consideration - SEC Filing

THOMSON REUTERS
·
May 14

Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss

MT Newswires Live
·
May 14

Allogene Q1 net loss $42.6 million, or $0.18 a share; cash $266.9 million

Reuters
·
May 14

BRIEF-Allogene Therapeutics Q1 EPS USD -0.18

Reuters
·
May 14